Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -10.00 -1.16% 850.00 850.00 860.00 855.00 850.00 850.00 39,326 16:35:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.3 -9.7 -17.3 - 632

Maxcyte Share Discussion Threads

Showing 526 to 549 of 650 messages
Chat Pages: 26  25  24  23  22  21  20  19  18  17  16  15  Older
DateSubjectAuthorDiscuss
11/2/2021
11:17
Agree very good interview with Maxcyte getting star billing also put me on to BYIT a company well under the radar I had not previously heard of. RM
rampmeister
10/2/2021
23:27
homebrewruss, Thanks for posting that link to the VOX Market interview with Dan Hanbury. Can't believe only 201 people have watched it on YouTube! I groaned inwardly when I saw that the video was 57 minutes long but it was really interesting (not just the MXCT bit) and I watched it to the bitter end. Dan Hambury seems like an investment manager who has his head screwed on and was very informative. His insights on Bitcoin and the use of Tethers were particularly informative (definitely to be avoided in my view). Well worth a watch.
thetrotsky
10/2/2021
17:46
well we know where the profit takers came from then : )
nimbo1
10/2/2021
13:23
MXCT mentioned in this interview with Dan Hanbury, UK Equity Fund Manager at River and Mercantile, from about 14:30 hTTps://www.youtube.com/watch?v=jMRe1vKLpNc&ab_channel=VoxMarkets
homebrewruss
10/2/2021
12:22
Can't keep a good man down....(for long)
assagai
10/2/2021
10:55
Well, there's no online quote available so pressure is on the upside.
someuwin
09/2/2021
16:54
MaxCyte @MaxCyte_info ยท8m Congratulations to our partner, Vor BioPharma, on hitting Wall Street with $177M IPO: http://ow.ly/Zu5l50DvGl1 via @FierceBiotech . #CellTherapy #AML #BloodCancer #CancerResearch
someuwin
09/2/2021
14:09
Thanks for flagging pob69
adamb1978
09/2/2021
13:45
11 March event with Maxctye hTTps://www.proactiveinvestors.co.uk/register/event_details/323
pob69
08/2/2021
16:34
Bloody hell - we pay them to do the research and then they come up with a valuation "leaving ample room for upside".
trident5
08/2/2021
16:19
“Our valuation approach leaves ample room for upside as MaxCyte continues to execute on its strategy. Pipeline progress at existing partners should translate into continued growth in instrument and consumable revenues. MaxCyte has begun to benefit from milestone receipts from these deals but is still to receive the more substantial payments associated with later-stages of development, as well as the commercial phase revenues as discussed earlier. As these partnerships mature, we expect further step-changes in MaxCyte’s revenue potential”
acuere
08/2/2021
15:54
"Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objectiveR17; in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research."
al101uk
08/2/2021
15:48
Is that research paid for by MAxcyte?
trident5
08/2/2021
15:37
Following on from the flash note last week, here is more comprehensive coverage, with Our £1bn ($1.3bn) valuation (1217p/share) better captures potential value from the partner pipeline. hTTps://www.trinitydelta.org/wp-content/uploads/2021/02/MaxCyte-Update-210208.pdf
pob69
08/2/2021
15:18
D1 capital partners above 3%, good news
nimbo1
08/2/2021
09:21
Added back the traders I sold on Friday
donald pond
08/2/2021
09:06
Bought a few more on the dip.
someuwin
07/2/2021
20:25
MaxCyte (and a few of their partners ?) attending this... https://cartcr-europe.com/whats-on/day-one/
someuwin
07/2/2021
16:38
Yep thanks sorry writing and checking from a phone sometimes = errors. Will correct :)
nimbo1
07/2/2021
16:06
Thanks nimbo1, just one issue though, I'm sure you mean Cellectis, the France based company right? Its valued at ~£800m not $10b. GLA
mginvestor
07/2/2021
15:58
Yep 😂 I thought they would change that old valuation. Thanks for the update
2theduke
07/2/2021
14:38
Listen from 35 mins where Cathy Wood talks about the future for Allogenic treatments being a $250 bil opportunity in the next 5-10 years. This is Maxcyte’s stomping ground… what could it mean if maxcyte maintained their 3-5% tax on the industry once commercial revenues flow, through the royalties and consumables? https://twitter.com/ARKInvest/status/1357857261729832960?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet Allogene have a deal in place with Maxcyte. And out of interest Allogene licence the technology from Collectis ($1bil Market cap) - Collectis have their own in house electroporation tech but allogene chose to go with Maxcyte. hTTps://maxcyte.com/maxcyte-and-allogene-therapeutics-sign-clinical-and-commercial-license-agreement-to-enable-the-advancement-of-allogeneic-car-t-allocar-t-therapies/ “MaxCyte’s ExPERT platform has become the industry standard in electroporation technology and allows us to increase efficiency and improve yield, which is a critical component to the value proposition of our AlloCAR T™ therapies,” said Alison Moore, Ph.D., Chief Technical Officer of Allogene.
nimbo1
06/2/2021
13:00
Interesting research note by Trinity Delta who specialise in equity research in healthcare and life sciences sectors They are suspending valuation and forecasts with the aim to re-introduce updated values as soon as practicable.(Sept was 402p) ",,,,The success of even a small portion of programmes under licence would be transformative for MaxCyte." hTTps://www.trinitydelta.org/wp-content/uploads/2021/02/MaxCyte-Lighthouse-210205.pdf
pob69
05/2/2021
17:58
Some major volume here today. 2 x 2m share buy at 9.85 first thing. Have a good weekend all.
2theduke
Chat Pages: 26  25  24  23  22  21  20  19  18  17  16  15  Older
ADVFN Advertorial
Your Recent History
LSE
MXCT
Maxcyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210418 03:02:33